News

Medication Side Effects Tied to Higher Blood Transfusion Rates

People with Parkinson’s disease who experience side effects from their medications are more likely to require a blood transfusion, a new analysis indicates. Digestive problems, particularly bleeding in the gut, also was associated with a higher likelihood of Parkinson’s patients needing a blood transfusion. “The findings of this study…

Relationship Between Disease Risk, Protective Factors Studied

A previously identified risk factor for the development of Parkinson’s disease  — indigestion — and two protective factors (exercise and caffeine consumption) are associated with the severity of symptoms after disease onset, a study has found. Caffeine use also was tied to a later age of disease onset. “Our…

Direct-to-brain Levodopa, Curcumin Treatment May Merit Closer Look

Nanoparticles that simultaneously deliver levodopa and curcumin, a potentially neuroprotective compound, directly to the brain may be “a promising novel therapy for treating Parkinson’s disease,” researchers in Brazil and France reported. The tiny particles created by these scientists might also help to overcome some of the drawbacks of current …

Two Exercise Programs Improve Dexterity, Quality of Life: Study

Two different types of rehabilitation-focused exercise programs — activity-based training and strength exercises — improved measures of dexterity and upper limb function in a small clinical trial of people with Parkinson’s disease. The study, “Effect of Activity-Based Training Versus Strengthening Exercises on Upper Extremity Functions in Parkinson’s Patients; A…

Stanford Initiative Focuses on How to Keep the Brain Resilient

A Stanford University research initiative will focus on the causes of neurodegeneration in diseases such as Parkinson’s and on the mechanisms behind some people’s brain resilience to aging and neurodegeneration. This information will be used to find ways to prevent, delay, or even reverse neurodegeneration and cognitive decline. “This…

UB-312 Vaccine Well Tolerated by Healthy Adults in Ongoing Trial

UB-312, an experimental vaccine targeting aggregated and toxic forms of alpha-synuclein to treat Parkinson’s disease, was generally well tolerated at multiple doses in a clinical trial in healthy adults. Study data also suggest that UB-312 prompted an immune response, as designed, against the alpha-synuclein protein. With two doses now selected…